CAMBRIDGE, Mass., Jan. 3 /PRNewswire/ -- Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, today announced that it will be presenting at the JPMorgan 24th Annual Healthcare Conference. Christoph Westphal, Chief Executive Officer of Sirtris, will provide an overview of the Company and discuss the Company’s strategy for discovering and developing novel therapeutics that modulate sirtuin pathways to harness the body’s own health-promoting genes. His presentation will be delivered at 1:30pm PST (4:30pm EST) on Tuesday, January 10th, 2006 in San Francisco.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body’s natural defense against disease. Also known as class III histone deacetylases (HDACs), sirtuins are attractive drug targets for a variety of unmet medical needs including metabolic and neurological diseases. Sirtris has built the dominant sirtuin intellectual property estate and know-how, with a comprehensive suite of reagents, proprietary assays, transgenic animal models, and biomarkers.
Founded by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair, and Christoph Westphal, Sirtris Pharmaceuticals has raised $45 million in private equity from leading venture capital firms, including Polaris Venture Partners, Techno Venture Management, Cardinal Partners, Skyline Ventures, Three Arch Partners, The Wellcome Trust, Novartis Bioventures Fund, Cargill Ventures, Hunt Ventures, and Red Abbey. The company’s headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.sirtrispharma.com.
Media Contact:
Kathryn Morris
845-635-9828
Sirtris Pharmaceuticals
CONTACT: Kathryn Morris for Sirtris Pharmaceuticals, +1-845-635-9828
Web site: http://www.sirtrispharma.com//
